Operation Warp Speed's latest move: $31M to Cytiva to manufacture COVID-19 vaccine components

SourceBecker's Hospital Review
Date Published10/15/2020
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Cytiva
Parent companyDanaher Corporation Life Sciences platform
Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2020
Year reshoring implemented or to be implemented:2021
Domestically, the work will be done:In-house
City reshored to:Marlborough
State(s) reshored to:MA
If relevant, work nearshored to:-
Product(s) reshoredvaccine components, cell culture buffers
What domestic positive factors made reshoring more attractive?Government Incentives, Impact on domestic economy, Lead time/Time to market, Proximity to customers/market, Under-utilized capacity, Other, Covid-19
Government Incentive dollar amount:$31 million
Find Reshoring Articles